Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis

Author:Kieseier, Bernd   Montalban, Xavier   Williams, Mitzi   Airas, Laura   Saini, Sarbjit   Hide, Michihiro   Sussman, Gordon   Nakahara, Jin   Bermel, Robert   Doerner, Thomas   Loop, Brett   DeLasHeras, Virginia   Willi, Roman   Haemmerle, Sibylle   Zharkov, Artem   Barbier, Nathalie   Azmon, Amin   Siegel, Richard   Cenni, Bruno   Wiendl, Heinz   Maurer, Marcus   Gimenez-Arnau, Ana   Chitnis, Tanuja   

Session Name:P8: Multiple Sclerosis: Non-MS CNS Neuroinflammatory Diseases and Progressive MS and Remyelination/Neuroprotection  

Topic:Multiple Sclerosis  

Program Number:P8.015  

Author Institution:Novartis Pharma AG, Basel, Switzerland  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain  Joi Life Wellness Group, Atlanta, GA  Turku University Hospital and University of Turku, Turku, Finland  Johns Hopkins Asthma and Allergy Center, Baltimore, MD  Hiroshima Citizens Hospital, Minami-ku, Japan  University of Toronto, Toronto, ON, Canada  Department of Neurology, Keio University School of Medicine, Tokyo, Japan  Mellen Center for MS, Cleveland Clinic, Cleveland, OH  Department of Rheumatology and Clinical Immunology, Charite – Universitätsmedizin Berlin, Berlin, Germany  Novartis Pharmaceutical Corporation, Cambridge, MA  Novartis Institutes for Biomedical Research, Basel, Switzerland  Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany  Urticaria Center of Reference and Excellence, Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany  Department of Dermatology, Hospital del Mar – IMIM, Universitat Pompeu Fabra, Barcelona, Spain  Department of Neurology, Brigham and Women's Hospital, Boston, MA  

GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis